PMID- 21486686
OWN - NLM
STAT- MEDLINE
DCOM- 20110705
LR  - 20110502
IS  - 1872-7980 (Electronic)
IS  - 0304-3835 (Linking)
VI  - 306
IP  - 1
DP  - 2011 Jul 1
TI  - Identification of therapy-sensitive and therapy-resistant neuroblastoma subtypes 
      in stages III, IVs and IV.
PG  - 27-33
LID - 10.1016/j.canlet.2011.02.016 [doi]
AB  - The aim was to present a new model of risk stratification with high predictive 
      sensitivity for non-localized neuroblastomas (NBs). "MYCN amplification", 
      "unfavorable histology of the International Neuroblastoma Pathology 
      Classification (INPC) system" and "low Ha-ras/trk A expression" could be defined 
      as an independent predictor for high-risk NBs. A risk stratification flow chart 
      was applied to 103 advanced NBs in which all three factors were examined and 69 
      were grouped as high-risk NBs of which 38 patients died. The predictive 
      sensitivity for poor patient outcome was 86%, which included 38 of the 44 total 
      deaths in this analysis. Using the number of the three independent risk factors 
      in each tumor, the 69 high-risk NBs were classified into three subgroups. NBs 
      with the three risk factors (triple risk) represented the most aggressive 
      character and survival of the affected patients was only 10% ("therapy-resistant 
      NBs"). Survivals of the patients with NBs possessed the two (double) risk factors 
      or the one (single) risk factor were 29% and 66%, respectively. This 
      stratification also elucidated a subgroup in which patient survival was 90% 
      ("therapy-sensitive"). There were 21 NBs with "high Ha-ras/trk A expression", 
      "favorable INPC histology" and "unamplified MYCN" (no risk NBs). Among the four 
      subgroups without a risk factor, with a single risk factor, with double risk and 
      with triple risk, Kaplan-Meier analysis showed a significant difference in NB 
      patient outcome (p<0.0001). Risk stratification might improve the therapeutic 
      efficacy for the high-risk NBs and might decrease therapy-related sequelae in the 
      lower risk NBs.
CI  - Copyright (c) 2011. Published by Elsevier Ireland Ltd.
FAU - Kyo, Yohko
AU  - Kyo Y
AD  - National Hospital Organization Hiroshimanishi Medical Center, Hiroshima, Japan.
FAU - Tanaka, Takeo
AU  - Tanaka T
FAU - Hayashi, Kunihiko
AU  - Hayashi K
FAU - Iehara, Tomoko
AU  - Iehara T
FAU - Kaneko, Michio
AU  - Kaneko M
FAU - Hosoi, Hajime
AU  - Hosoi H
FAU - Sugimoto, Tohru
AU  - Sugimoto T
FAU - Hamasaki, Minoru
AU  - Hamasaki M
FAU - Kobayashi, Masao
AU  - Kobayashi M
FAU - Sawada, Tadashi
AU  - Sawada T
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20110412
PL  - Ireland
TA  - Cancer Lett
JT  - Cancer letters
JID - 7600053
RN  - 0 (Antineoplastic Agents)
SB  - IM
MH  - Antineoplastic Agents/pharmacology
MH  - Child
MH  - Child, Preschool
MH  - Decision Support Techniques
MH  - Disease-Free Survival
MH  - *Drug Resistance, Neoplasm
MH  - Female
MH  - Humans
MH  - Infant
MH  - Infant, Newborn
MH  - Male
MH  - Neoplasm Staging/*methods
MH  - Neuroblastoma/*diagnosis/*drug therapy/mortality
MH  - Prognosis
MH  - Risk Factors
MH  - Sensitivity and Specificity
MH  - Treatment Outcome
EDAT- 2011/04/14 06:00
MHDA- 2011/07/06 06:00
CRDT- 2011/04/14 06:00
PHST- 2010/11/27 00:00 [received]
PHST- 2011/02/11 00:00 [revised]
PHST- 2011/02/15 00:00 [accepted]
PHST- 2011/04/14 06:00 [entrez]
PHST- 2011/04/14 06:00 [pubmed]
PHST- 2011/07/06 06:00 [medline]
AID - S0304-3835(11)00089-9 [pii]
AID - 10.1016/j.canlet.2011.02.016 [doi]
PST - ppublish
SO  - Cancer Lett. 2011 Jul 1;306(1):27-33. doi: 10.1016/j.canlet.2011.02.016. Epub 
      2011 Apr 12.